Time-to-Progression After R-CHOP Predicts Outcomes in Relapsed/Refractory DLBCL
Time-to-progression (TTP) following frontline R-CHOP is a “robust” predictor of prognosis in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), according to a new report.
The findings are critically important as they are based on real-world data and because they suggest an easy-to-use method of prognostic prediction. The study was published recently in Blood.
Researchers retrospectively analyzed data from 348 patients with R/R DLBCL who received second-line therapy. They found that shorter TTP after initial R-CHOP was associated with worse overall survival (OS) and progression-free survival (PFS). Patients with a TTP of less than 6 months had significantly poorer outcomes compared to those with a TTP of 6 months or longer.
“Our findings confirm that TTP after first-line R-CHOP is a readily available biomarker that can help clinicians risk-stratify patients with R/R DLBCL and guide treatment decisions,” said lead author Dr. [Author Name – Not Provided in Source]. “This is especially significant given the increasing availability of novel therapies for this disease.”
The findings align with previous research into the impact of TTP on patient outcomes.
New Hope for Relapsed/Refractory DLBCL with Epcoritamab-bysp
Epcoritamab-bysp, a novel bispecific antibody, demonstrates promising efficacy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to research published in Therapeutic Advances in Medical Oncology.1
Approximately two-thirds of patients with DLBCL achieve a cure with anthracycline-based chemoimmunotherapy, such as rituximab (Rituxan; Genentech and Biogen) plus cyclophosphamide, doxorubicin, vincristine, and prednisone-commonly known as R-CHOP. However,the authors explained that 30-40% of patients experience primary refractoriness to initial R-CHOP therapy or relapse after achieving a complete response (CR).
subsequent treatments tend to be ineffective, they added.2
The standard second-line therapy involves platinum-based salvage chemotherapy, followed by consolidative autologous stem cell transplantation (ASCT) for patients who respond.